KAINOS Laboratories, INC.
4556・Standard Market・Pharmaceuticals
Manufacturing and Sales of Clinical Diagnostic Reagents (Single Segment)
A single-business company engaged in the manufacturing and sale of in vitro diagnostic pharmaceuticals and medical devices
| Period | Current | Previous | Change |
|---|---|---|---|
| Net Sales | ¥5,479 million | ¥5,305 million | ↑ |
| Operating Income | ¥747 million | ¥823 million | ↓ |
| Operating Margin | 13.6% | 15.5% | ↓ |
| Ordinary Income | ¥788 million | ¥828 million | ↓ |
| Net Income | ¥449 million | ¥641 million | ↓ |
| Equity Ratio | 75.7% | 77.1% | ↓ |
| Earnings Per Share | ¥106.19 | ¥152.06 | ↓ |
| Total Assets | ¥9,566 million | ¥8,785 million | ↑ |
| Net Assets | ¥7,238 million | ¥6,775 million | ↑ |
| Cash and Cash Equivalents at End of Period | ¥3,400 million | ¥3,056 million | ↑ |
Business Details
Kainos Laboratories, Inc. (Code: 4556) is engaged in the integrated development, manufacturing, and sale of in vitro diagnostic pharmaceuticals and medical devices, centered on biochemical test reagents and immunoserological test reagents. Its major sales channels include related-party transactions with Toho Yakuhin Co., Ltd. and Asahi Kasei Therapeutics Co., Ltd. (formerly Asahi Kasei Pharma Corporation). Sales to domestic medical institutions account for the majority of net sales. Net sales for FY2026 (ending March 2026) were ¥5,479 million (up 3.3% year on year). The company is currently undergoing delisting procedures following a tender offer by Flowers Co., Ltd.
Recent Overview
Net sales increased, but net income fell 29.9% year on year due to ¥154 million in tender-offer-related expenses
In FY2026 (ending March 2026), the immunological test field (up 8.5% year on year) and other fields (up 7.6% year on year) drove net sales to ¥5,479 million (up 3.3% year on year). However, an increase in cost of sales (cost of products manufactured during the period rose 15.0% year on year to ¥2,426 million) reduced gross profit, resulting in operating income of ¥747 million (down 9.2% year on year). Furthermore, the recording of ¥154 million in extraordinary loss related to expenses associated with the tender offer by Flowers Co., Ltd. caused net income to fall to ¥449 million (down 29.9% year on year). As a result of the tender offer, Flowers Co., Ltd. acquired 72.46% of the company's shares, and the company is scheduled to be delisted on June 11, 2026.
Key Products
Growth Drivers
- Expansion of the immunological test field: blood transfusion test reagents and tumor marker reagents, among others, performed well, achieving approximately ¥2,987 million in sales (up 8.5% year on year) in FY2026 (ending March 2026)
- Expanding market share for LATECLE PCT Reagent (Procalcitonin Kit): continued active academic and sales activities for this sepsis diagnostic product
- Growth in other fields: sales of approximately ¥301 million (up 7.6% year on year) recorded in FY2026 (ending March 2026)
- Potential strengthening of the business foundation through becoming a wholly owned subsidiary of Flowers Co., Ltd. (a Denka Company Limited group company)
Risks
- Downward pressure on selling prices due to medical cost containment policies such as reimbursement price revisions
- Rising raw material costs due to the continued weak yen and surging resource prices (cost of products manufactured during the period increased 15.0% year on year in FY2026, ending March 2026)
- Limited room for growth due to the maturation and saturation trend in the domestic clinical diagnostic reagent market (the biochemical test field declined 3.6% year on year)
- Reduced information disclosure and loss of market liquidity associated with delisting
- Risk of fluctuations in profit levels due to the recording of one-time expenses related to the tender offer
- Risk of dependence on business partners due to sales concentration with major sales channels
Last updated: June 20, 2025